| Nr. Crt. | Nume | Status | Locatie |
| 1 | Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) | Activ, inca nu recruteaza | SpitalulJudetean de Urgenta „Dr. Constantin Opris” Baia Mare Baia Mare, Romania, 430031 S.C Policlinica de Diagnostic Rapid S.A Brasov, Romania, 500152 Institutul Oncologic „Prof. Dr. Al. Trestioreanu” Bucuresti, Romania, 022328 Spitalul Clinic Coltea Bucuresti, Romania, 030171 S.C Gral Medical S.R.L Bucuresti, Romania, 031422 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj Napoca Cluj Napoca, Romania, 400015 S.C Medisprof S.R.L Cluj-Napoca, Romania, 400058 SpitalulMilitar de Urgenta „Dr.ConstantinPapilian”Cluj -Napoca Cluj-Napoca, Romania, 400132 S.C Radiotherapy Center Cluj S.R.L ComunaFloresti, Romania, 407280 Spitalul Clinic Judetean de Urgenta „Sf. Apostol Andrei” Constanta Constanta, Romania, 900591 S.C Centrul de Oncologie Sf. Nectarie S.R.L Craiova, Romania, 200347 Institutul Regional de Oncologie Iasi Iasi, Romania, 700483 S.C Pelican Impex S.R.L Oradea, Romania, 410469 Spitalul Clinic Municipal „Dr. Gavril Curteanu” Oradea Oradea, Romania, 410469 SpitalulJudetean de Urgenta „Sf. IoancelNou” Suceava Suceava, Romania, 720201 S.C OncocenterOncologieClinica S.R.L Timisoara, Romania, 300210 S.C Oncomed S.R.L Timisoara, Romania, 300239 |
| 2 | An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 010991 Local Institution Bucharest, Romania, 020122 Local Institution Craiova, Romania, 200347 Local Institution Lasi, Romania, 700106 Local Institution Romania, Romania, 400015 Local Institution Timisoara, Timis, Romania, 300239 |
| 3 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | Activ, inca nu recruteaza | ImClone Investigational Site Brasov, Romania, 500366 ImClone Investigational Site Bucharest, Romania, 022328 ImClone Investigational Site Bucharest, Romania, 030171 ImClone Investigational Site Cluj-Napoca, Romania, 400015 ImClone Investigational Site Craiova, Dolj, Romania, 200385 ImClone Investigational Site Iasi, Romania, 700106 ImClone Investigational Site Piatra Neamt, Romania, 610136 ImClone Investigational Site Sibiu, Romania, 550245 |
| 4 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | In curs de recrutare | S.C Gral Medical S.R.L Bucuresti, Romania Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania S.C Medisprof S.R.L Cluj-Napoca, Romania S.C Centrul de Oncologie Sf. Nectarie Craiova, Romania S.C Radiotherapy Center Cluj S.R.L Floreşti, Romania S.C OncocenterOncologieClinica S.R.L Timisoara, Romania Oncomed SRL Timişoara, Romania |
| 5 | First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin | Activ, inca nu recruteaza | ImClone Investigational Site Brasov, Romania, 500366 ImClone Investigational Site Bucharest, Romania, 022328 ImClone Investigational Site Bucharest, Romania, 030171 ImClone Investigational Site Cluj-Napoca, Romania, 400015 ImClone Investigational Site Craiova, Dolj, Romania, 200385 ImClone Investigational Site Iasi, Romania, 700106 ImClone Investigational Site Sibiu, Romania, 550245 |
| 6 | Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A | In curs de recrutare | Novartis Investigative Site Floresti, Cluj, Romania, 407280 Novartis Investigative Site Bucharest, Romania, 022328 Novartis Investigative Site Bucuresti, Romania, 010991 Novartis Investigative Site Cluj-Napoca, Romania, 400124 Novartis Investigative Site Craiova, Romania, 200347 Novartis Investigative Site Iasi, Romania, 700483 Novartis Investigative Site Timisoara, Romania, 300239 |
| 7 | Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) | In curs de recrutare | Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoc ( Site 0501) Cluj Napoca, Cluj, Romania, 400015 Contact: Study Coordinator +40745976913 SC Radiotherapy Center Cluj SRL ( Site 0509) ComunaFloresti, Cluj, Romania, 407280 Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0504) Craiova, Dolj, Romania, 200347 S.C.R.T.C.Radiology Therapeutic Center SRL ( Site 0511) Otopeni, Ilfov, Romania, 075100 Contact: Study Coordinator +40723171603 S.C.Focus Lab Plus S.R.L ( Site 0513) Bucuresti, Sector 2, Romania, 021389 Contact: Study Coordinator +40721298677 S C OncocenterOncologieMedicala S R L ( Site 0505) Timisoara, Timis, Romania, 300166 Contact: Study Coordinator +40745146020 Spitalul Sf. Constantin ( Site 0512) Brasov, Romania, 500091 Contact: Study Coordinator +40724630750 Euroclinic Hospital Bucharest ( Site 0510) Bucuresti, Romania, 014461 Contact: Study Coordinator +40744848887 Affidea Romania SRL ( Site 0514) Bucuresti, Romania, 022328 Contact: Study Coordinator +40743424144 Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoc ( Site 0515) Cluj-Napoca, Romania, 400015 Contact: Study Coordinator +40745646368 Spitalul clinic Judetean de urgenta Constanta ( Site 0508) Constanta, Romania, 900591 Contact: Study Coordinator +40724877013 S C Pelican Impex SRL ( Site 0506) Oradea, Romania, 410450 Contact: Study Coordinator +40746103306 SpitalulJudetean de Urgenta .Sf. IoancelNou. ( Site 0503) Suceava, Romania, 720237 Contact: Study Coordinator +40722423653 |
| 8 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | In curs de recrutare | Centrul de Oncologie Sf. Nectarie SRL Craiova, Dolj, Romania, 200347 Contact 40351401336 Principal Investigator: Michael Schenker Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 Contact 40723289606 Principal Investigator: Aurelia Alexandru SC Gral Medical SRL Bucuresti, Romania, 031422 Contact 40213230000 Principal Investigator: Cristina Tiut SpitalulUniversitar de UrgentaBucuresti Bucuresti, Romania, 050098 Contact 4072145891 Principal Investigator: PolixeniaGeorgetaIorga Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca, Romania, 400015 Contact 40745646368 Principal Investigator: Tudor Ciuleanu Spitalul Clinic Judetean de UrgentaSf.Apostol Andrei Constanta, Romania, 900591 Contact 40241662222 Principal Investigator: Laura Mazilu SpitalulJudetean de Urgenta „Sf. IoancelNou” Suceava, Romania, 720237 Contact 40230515554 Principal Investigator: Doina Elena Ganea-Motan Oncomed SRL Timisoara, Romania, 300239 Contact 40256495403 Principal Investigator: Cristina Oprean |
| 9 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 022328 Local Institution Bucharest, Romania, 030171 Local Institution Cluj Napoca, Romania, 400058 Local Institution Cluj-Napoca, Romania, 400015 Local Institution Oradea, Romania, 410469 Local Institution Timisoara, Romania, 300167 |
| 10 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | Activ, inca nu recruteaza | Research Site Alba Iulia, Romania, 510077 Research Site Baia Mare, Romania, 430031 Research Site Cluj Napoca, Romania, 400349 Research Site Cluj-Napoca, Romania, 400132 Research Site Onesti, Romania, 601048 Research Site Oradea, Romania, 410469 Research Site Timisoara, Romania, 300210 |
| 11 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | Activ, inca nu recruteaza | Local Institution Bucuresti, Romania, 010976 Local Institution Cluj-Napoca, Romania, 400352 Local Institution Constanta, Romania, 900591 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167 |
| 12 | A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] | Activ, inca nu recruteaza | Teo Health SA – Saint Constantin Hospital Brasov, Romania, 500091 Prof. Dr. I. Chiricuta Institute of Oncology Cluj Napoca, Romania, 400015 Oncology Center Sf. Nectarie Craiova, Romania, 200347 Institutul Regional de Oncologie Iasi; Clinica de Hematologie Iasi, Romania, 700483 Sibiu Emergency Clinical County Hospital Sibiu, Romania, 550245 Oncomed SRL Timisoara, Romania, 300239 Oncocenter Clinical Oncology Timişoara, Romania, 300210 |
| 13 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer | Activ, inca nu recruteaza | Focus Lab Plus SRL Bucuresti, Romania, 021389 Sf. Nectarie Oncology Center Craiova, Romania, 200347 Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep Romania, Romania, 400015 |
| 14 | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Activ, inca nu recruteaza | Research Site Bucharest, Romania, 050098 Research Site Bucuresti, Romania, 022328 Research Site Craiova, Romania, 200347 |
| 15 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | In curs de recrutare | Institute Of Oncology „Prof.Dr.AlexandruTrestioreanu” Bucha Bucharest, Romania, 022328 Sf. Nectarie Oncology Center Craiova, Romania, 200347 S.C. Radiotherapy Center Cluj S.R.L. Floresti, Romania, 407280 Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep Romania, Romania, 400015 |
| 16 | A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy | Activ, inca nu recruteaza | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; OncologieMedicala Completed Cluj Napoca, Romania, 400015 Centrul de Radioterapie AMETHYST Completed Floresti, Romania, 407280 Oncocenter Timisoara Completed Timişoara, Romania, 300166 |
| 17 | A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | Activ, inca nu recruteaza | Medisprof SRL Cluj-Napoca, Romania, 400058 Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta Constanta, Romania, 900591 Euroclinic Center of Oncology SRL Iasi, Romania, 700106 |
| 18 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | Activ, inca nu recruteaza | Local Institution Cluj Napoca, Romania, 400015 Local Institution Cluj-napoca, Romania, 400352 Local Institution Ploiesti, Romania, 100337 |
| 19 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER) | Activ, inca nu recruteaza | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician. Baia Mare, Romania, 430031 Bucharest, Romania, 022328 Cluj-Napoca, Romania, 400015 Cluj-Napoca, Romania, 400058 Craiova, Romania, 200347 |
| 20 | Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC | Activ, inca nu recruteaza | Conformal Med Terra HIFU Bucharest, Romania, 031864 Spitalul de Psihiatrie Dr. Constantin Gorgos Bucharest, Romania, 30447 Oncology Institute Bucharest Bucharest, Romania Oncological Institute „Ion Chiricuta” Cluj-Napoca, Romania, 3400 OCH – Ovidius Clinical Hospital Constanta, Romania, 905900 Centrul de Oncologie Sf Nectarie Craiova, Romania, 200347 SC Oncolab SRL Craiova, Romania, 200385 Spital Lotus SRL Ploiesti, Romania, 100011 |
| 21 | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | In curs de recrutare | Local Institution Bucharest, Romania, 022328 Contact: Site 0018 Local Institution Cluj-Napoca, Romania, 400015 Contact: Site 0019 Local Institution Constanta, Romania, 900591 Contact: Site 0020 Local Institution Craiova, Romania, 200347 Contact: Site 0017 Local Institution Floresti, Romania, 407280 Contact: Site 0021 |
| 22 | Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC | Activ, inca nu recruteaza | Local Institution Bucuresti, Romania, 010976 Local Institution Cluj-Napoca, Romania, 400352 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167 |
| 23 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | Activ, inca nu recruteaza | Clinical Study Site 1 Craiova, Romania Clinical Study Site 2 Craiova, Romania Clinical Study Site Floreşti, Romania Clinical Study Site Ploieşti, Romania Clinical Study Site Timişoara, Romania |
| 24 | Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer | In curs de recrutare | Institutul Oncologic /ID# 206320 Cluj Napoca, Romania, 400015 Oncomed SRL /ID# 205616 Timisoara, Romania, 300239 |
| 25 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | Activ, inca nu recruteaza | Institute Of Oncology „Prof.Dr.AlexandruTrestioreanu” Bucha Bucharest, Romania, 020122 Sf. Nectarie Oncology Center Craiova, Romania, 200347 Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep Romania, Romania, 400015 |
| 26 | Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 020122 Local Institution Craiova, Romania, 200347 |
| 27 | A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | Activ, inca nu recruteaza | Institutul Oncologic „Prof. Dr. Ion Chiricuţă” Cluj Napoca Recruiting Cluj-Napoca, Romania, 400015 Contact: Dr Tudor-Eliade Ciuleanu Medisprof SRL Recruiting Cluj-Napoca, Romania, 400641 Contact: Dr. Anghel Adrian Udrea Centrul de Oncologie, S.C. Centrul de Oncologie Sf. Nectarie S.R.L, Recruiting Craiova, Romania, 200347 Contact: Dr Michael Schenker Oncocenter – OncologieClinica SRL Recruiting Timişoara, Romania, 300166 Contact: Dr Roxana Scheusan |
| 28 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) | In curs de recrutare | Prof Dr I Chiricuta Institute of Oncology Cluj-Napoca, Romania, 400015 Sf. Nectarie Oncology Center Craiova, Romania, 200347 |
| 29 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | Activ, inca nu recruteaza | Local Institution Active, not recruiting Bucharest, Romania, 020122 Local Institution Active, not recruiting Cluj-Napoca, Romania, 400015 Local Institution Active, not recruiting Craiova, Romania, 200347 |
| 30 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | In curs de recrutare | Spitalul PDR Medlife ( Site 2509) Brasov, Romania, 500152 Contact: Study Coordinator +40722559551 S.C.Focus Lab Plus S.R.L ( Site 2502) Bucuresti, Romania, 021389 Contact: Study Coordinator +40721298677 Cardiomed SRL Cluj-Napoca ( Site 2504) Cluj Napoca, Romania, 400015 Contact: Study Coordinator +40724543672 S.C. Radiotherapy Center Cluj S.R.L ( Site 2507) Cluj-Napoca, Romania, 407280 Contact: Study Coordinator +40742206212 Spitalul Clinic Judetean De Urgenta Constanta ( Site 2501) Constanta, Romania, 900591 Contact: Study Coordinator +40724877013 PoliclinicaOncomed SRL ( Site 2505) Timisoara, Romania, 300239 Contact: Study Coordinator +40724543672 |
| 31 | Phase II Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC) | In curs de recrutare | GSK Investigational Site Bucharest, Romania, 020142 GSK Investigational Site Cluj-Napoca, Romania, 400641 GSK Investigational Site Craiova, Romania, 200347 GSK Investigational Site Floresti, Romania, 407280 GSK Investigational Site Otopeni, Romania, 075100 GSK Investigational Site Timisoara, Romania, 300166 |
| 32 | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC | Activ, inca nu recruteaza | Research Site Cluj Napoca, Romania, 400015 Research Site Cluj Napoca, Romania, 400058 |
| 33 | AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. | Activ, inca nu recruteaza | Research Site Bucharest, Romania, 050098 Research Site Bucuresti, Romania, 031422 Research Site Cluj Napoca, Romania, 400015 Research Site Craiova, Romania, 200385 Research Site Focsani, Romania, 620165 Research Site Iasi, Romania, 700483 Research Site Timisoara, Romania, 300210 |
| 24 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | Activ, inca nu recruteaza | Novartis Investigative Site Cluj-Napoca, Romania, 400124 Novartis Investigative Site Craiova, Romania, 200347 |
| 35 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) | Activ, inca nu recruteaza | Research Site Cluj Napoca, Romania, 400015 Research Site Floresti, Romania, 407280 Research Site Suceava, Romania, 720237 |
| 36 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Activ, inca nu recruteaza | Centrul de OncologieSfantulNectarie Craiova, Dolj, Romania, 200347 Oncolab SRL Craiova, Dolj, Romania, 200385 Medisprof SRL Cluj-Napoca, Romania, 400461 Clinical Emergency Hospital of Constanta Constanta, Romania, 900591 Center of Oncology Euroclinic Iasi, Romania, 700106 Spitalul Clinic Judetean de Urgenta Sibiu Sibiu, Romania, 550245 Oncocenter – OncologieClinica SRL Timisoara, Romania, 300166 |
| 37 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) | Activ, inca nu recruteaza | S.C. MedisProf SRL Cluj-Napoca, Cluj, Romania, 400058 Institutul Oncologic Dr TrestioreanuBucuresti Bucuresti, Sector 2, Romania, 022328 |
| 38 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | In curs de recrutare | S.C.Focus Lab Plus S.R.L ( Site 2502) Bucuresti, Romania, 021389 Contact: Study Coordinator +40721298677 Cardiomed SRL Cluj-Napoca ( Site 2504) Cluj Napoca, Romania, 400015 Contact: Study Coordinator +40728209986 S.C. Radiotherapy Center Cluj S.R.L ( Site 2507) Cluj-Napoca, Romania, 407280 Contact: Study Coordinator +40372693518 Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei ( Site 2501) Constanta, Romania, 900591 Contact: Study Coordinator +40724877013 PoliclinicaOncomed SRL ( Site 2505) Timisoara, Romania, 300239 Contact: Study Coordinator +40744571617 |
| 39 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal) | In curs de recrutare | County Hospital Alba; Oncology Alba Iulia, Romania, 510073 Centrul Medical Focus; Oncologiemedicala Bucharest, Romania, 021389 University Clinical Emergency Hospital Bucharest Bucharest, Romania Institutul Oncologic Prof. Dr. Al. TrestioreanuBucuresti Bucuresti, Romania, 022328 Sanador Medical Center; Medical Oncology Bucuresti, Romania Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta Constanta, Romania, 900591 Institutul Regional de Oncologie Iasi Iasi, Romania, 700483 Spitalul Municipal Ploiesti Ploiesti, Romania, 100337 Oncomed SRL; Oncologie Timisoara, Romania, 300239 Oncocenter Timisoara Timişoara, Romania, 300166 |
| 40 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | In curs de recrutare | Local Institution Bucharest, Romania, 724351 Contact: Site 0011 Local Institution Cluj-Napoca, Romania, 400015 Contact: Site 0013 Local Institution Floresti, Romania, 407280 Contact: Site 0012 |
| 41 | Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | Activ, inca nu recruteaza | Oncology Center Sf. Nectarie Craiova, Romania, 200347 |
| 42 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | Activ, inca nu recruteaza | Research Site 6105 Cluj-Napoca, Cluj, Romania, 400058 Research Site 6106 Cluj-Napoca, Cluj, Romania, 400352 Research Site 6108 Floreşti, Cluj, Romania, 407280 Research Site 6101 Baia Mare, Romania, 430031 Research Site 6102 Constanta, Romania, 900591 Research Site 6103 Craiova, Romania, 200385 Research Site 6107 Iasi, Romania, 700106 |
| 43 | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). | Activ, inca nu recruteaza | Research Site Suceava, Romania, 720237 |
| 44 | Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331) | Activ, inca nu recruteaza | Local Institution Bucharest, Romania, 020122 Local Institution Craiova, Romania, 200347 Local Institution Romania, Romania, 400015 Local Institution Timisoara, Timis, Romania, 300239 |
| 45 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | In curs de recrutare | Institutul Oncologic Prof. Dr. Alexandru Trestioreanu; Oncologie Medicala II Withdrawn Bucuresti, Romania, 022328 Cardiomed Medical Center Recruiting Cluj-Napoca, Romania, 400015 Prof Dr I Chiricuta Institute of Oncology; Oncology Department Not yet recruiting Cluj-napoca, Romania, 400015 Oncomed SRL; Oncologie Not yet recruiting Timisoara, Romania, 300239 Municipal Clinical Emergency Hospital Timisoara; Medical Oncology Clinic Not yet recruiting Timişoara, Romania, 300595 |
| 46 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | In curs de recrutare | Research Site Recruiting Bucharest, Romania, 022328 Research Site Recruiting Bucharest, Romania, 022338 Research Site Recruiting Bucharest, Romania, 030171 Research Site Recruiting Cluj Napoca, Romania, 400015 Research Site Recruiting Iasi, Romania, 700483 Research Site Recruiting Ploiesti, Romania, 100337 Research Site Recruiting Timisoara, Romania, 300239 |
| 47 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | In curs de recrutare | „Prof. Dr. Ion Chiricuta” Institute of Oncology, Medical Oncology Department Recruiting Cluj-Napoca, Cluj County, Romania, 400015 „Sf. Nectarie” Oncology center, Medical Oncology department Recruiting Craiova, Dolj County, Romania, 200347 SC Oncopremium team SRL, Medical oncology department Recruiting Baia Mare, Maramures, Romania, 430291 Topmed Medical center, Medical Oncology Department Recruiting Târgu-Mureş, Murers, Romania, 540156 Sf. Ioan cel Nou Country Emergency Hospital, Oncology department Recruiting Suceava, Suceava County, Romania, 720237 S.C. Oncomed SRL, Medical Oncology Department Recruiting Timisoara, Timis, Romania, 300239 Alexandru Trestioreanu Institute of Oncology Recruiting Bucharest, Romania, 022328 |
| 48 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | Activ, inca nu recruteaza | Regeneron Research Site Bucuresti, Romania, 031422 Regeneron Research Site Cluj Napoca, Romania, 400124 Regeneron Research Site Craiova, Romania, 200094 Regeneron Research Site Craiova, Romania, 200347 Regeneron Research Site Craiova, Romania, 200385 Regeneron Research Site Iasi, Romania, 700106 Regeneron Research Site Iasi, Romania, 700483 Regeneron Research Site Timisoara, Romania, 300166 |
| 49 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1) | In curs de recrutare | Research Site Not yet recruiting Constanta, Romania, 900591 Research Site Not yet recruiting Floresti, Romania, 407280 Research Site Not yet recruiting Suceava, Romania, 720237 |
| 50 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Activ, inca nu recruteaza | Local Institution Craiova, Romania, 200094 Contact: Site 0012 Local Institution Craiova, Romania, 200347 Contact: Site 0052 Local Institution Craiova, Romania, 200385 Contact: Site 0017 Local Institution Timisoara, Romania, 300166 Contact: Site 0069 |
| 51 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) | In curs de recrutare | Investigational Site Number 6420002 Recruiting Bucuresti, Romania, 10991 Investigational Site Number 6420006 Recruiting Craiova, Romania, 200347 Investigational Site Number 6420005 Recruiting Timisoara, Romania, 300166 Investigational Site Number 6420004 Recruiting Timisoara, Romania, 300239 |
| 52 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS) | Activ, inca nu recruteaza | Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala Cluj Napoca, Romania, 400015 Centrul de Radioterapie AMETHYST Floresti, Romania, 407280 Oncocenter Timisoara Timişoara, Romania, 300166 |
| 53 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (CheckMate 79X) | In curs de recrutare | Local Institution Craiova, Romania, 200347 Contact: Site 0025 Local Institution Timisoara, Romania, 300696 Contact: Site 0018 |
| 54 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304) | In curs de recrutare | S C Oncocenter Oncologie Medicala S R L Recruiting Timisoara, Romania, 300166 |
| 55 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | In curs de recrutare | Research Site Not yet recruiting Suceava, Romania, 720237 |
| 56 | An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3) | In curs de recrutare | Institutul Oncologic Prof. Dr. Ion Chiricu Recruiting Cluj-Napoca, Cluj, Romania, 400015 Oncocenter- Oncologie Clinic Recruiting Timişoara, Timis, Romania, 300166 Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucaresti Recruiting Bucuresti, Romania, 022328 Centrul de oncologie Euroclinic Recruiting Iasi, Romania, 700106 |
| 57 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC (DOMAJOR) | In curs de recrutare | S.C Medisprof S.R.L Recruiting Cluj-Napoca, Romania Contact: Udrea A Anghel, MD S.C Radiotherapy Center Cluj S.R.L Recruiting Cluj, Romania Contact: Manolescu A Alexandru, MD „Sfantul Nectarie” Oncology Center SRL Recruiting Craiova, Romania Contact: Schenker Michael, MD S.C Oncolab S.R.L Recruiting Craiova, Romania Contact: Lungulescu Stefan, MD S.C Pelican Impex S.R.L Recruiting Oradea, Romania Contact: Puscas I Adriana, MD Emergency Clinical Municipal Hospital Timisoara – Medical Oncology Clinic Recruiting Timisoara, Romania Contact: Curescu Petra, MD S.C Oncocenter Clinical Oncology S.R.L Recruiting Timisoara, Romania Contact: Scheusan R Ioana, MD S.C Oncomed S.R.L Recruiting Timisoara, Romania Contact: Segarceanu N Alina, MD S.C Salvosan Ciobanca S.R. Recruiting Zalau, Romania Contact: Papp Margareta, MD |
(Visited 89 times, 1 visits today)